NPPB and obesity due to melanocortin 4 receptor deficiency: The currently observed decreases in NT-pro-BNP following treatment with orforglipron (perhaps more convincingly in the obesity study, ~ 19% reduction at highest doses) further suggest a potential for cardiovascular benefit.